Related Experiment Video
Updated: Apr 8, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
10.8K
Extrapolation of acenocoumarol pharmacogenetic algorithms
Enrique Jiménez-Varo1, Marisa Cañadas-Garre1, Víctor Garcés-Robles1
1Pharmacogenetics Unit, UGC Provincial de Farmacia de Granada, Instituto de Investigación Biosanitaria de Granada, Complejo Hospitalario Universitario de Granada, Avda. Fuerzas Armadas, 2, 18014 Granada, Spain.
Vascular Pharmacology
|July 1, 2015
Summary
Pharmacogenetic algorithms can guide acenocoumarol (ACN) dosing. The EU-PACT and Borobia algorithms showed the best accuracy and clinical performance for ACN therapy in this study.
Area of Science:
- Pharmacogenomics
- Clinical Pharmacology
- Drug Dosing
Background:
- Acenocoumarol (ACN) has a narrow therapeutic index, making initial dosing challenging.
- Pharmacogenetic-guided dosing algorithms exist but require external validation.
- Evaluating algorithm extrapolation is crucial for personalized medicine.
Purpose of the Study:
- To assess the external validation and extrapolation potential of existing pharmacogenetic algorithms for ACN dosing.
- To compare the predictive performance of five different pharmacogenetic algorithms.
Main Methods:
- Compared five pharmacogenetic algorithms (EU-PACT, Borobia, Rathore, Markatos, Krishna Kumar).
- Evaluated predictive performance, deviation, accuracy, and clinical significance.
- Included 189 stable ACN patients across all treatment indications.
Main Results:
- Correlation between predicted and actual ACN doses varied widely (7.7%–70.6%).
- Accurate ACN dose prediction (≤20% deviation) ranged from 5.9% to 40.7%.
- EU-PACT and Borobia algorithms demonstrated the highest accuracy and best clinical performance.
Conclusions:
- EU-PACT and Borobia pharmacogenetic dosing algorithms show the most promise for extrapolation.
- These algorithms offer a viable alternative to developing population-specific ACN dosing strategies.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
88
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
88
01:27Pharmacogenetics of Drug Metabolism: Overview
137
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
137
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
119
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
119
01:29Pharmacogenetics and Pharmacogenomics: Overview
162
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
162
01:27Principles of Pharmacogenetics: Types of Genetic Variants
102
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
102
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69